The type of ovarian cancer that is drawing researchers' attention is formally known as high-grade serous ovarian cancer, or ...

If approved, the combination regimen would be the first FDA-approved treatment for adults with recurrent KRAS mutant low-grade serous ovarian cancer (LGSOC).

Some 12% of women on the fast-track pathway were diagnosed with some kind of ovarian cancer. A total of 6.8% of fast-tracked ...

However, researchers at the Penn Ovarian Cancer Research Center at the University of Pennsylvania are studying a surprising ...

At first, doctors told her she had low-grade serous ovarian cancer, but she later learned she had borderline ovarian tumors. Campbell pursued a second and third opinion, which is how she was able ...

The guideline authors used data from 61 studies to provide recommendations on the use of neoadjuvant chemotherapy in patients with newly diagnosed, stage III-IV epithelial ovarian, fallopian tube, or ...

However, within individual cancer types, the occurrence of each mutation was variable, highlighted by a high frequency of TP53 SNV in ovarian high grade serous carcinoma (90 percent) and a low ...

While genetic testing rates for advanced ovarian cancer have increased, gaps in physician understanding and confidence in interpreting results may limit optimal biomarker-driven treatment and patient ...

There are currently no FDA-approved treatments specifically for LGSOC, a rare and distinct ovarian cancer that differs from high-grade serous ovarian cancer in both its biology and how it responds ...